Alzheimer

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer's disease

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease

Within the treated patient group, trends showed improved cognitive and executive functions, improved language comprehension, and verbal memory, in comparison to the placebo group REGEnLIFE, a french company specialized in the research and development of innovative photo-medical technologies for the prevention and treatment of neurodegenerative diseases, announces today the promising results of the pilot clinical…

Latest News